2019

1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

   The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911